You are now leaving XifaxanHE.com

Thank you for visiting XifaxanHE.com. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).

OKCancel

ABOUT HE

What are the risks of overt hepatic encephalopathy (HE)?

It’s important to understand the risks of overt HE so that you understand why ongoing management can help reduce those risks. Once an overt HE episode has occurred, there is a risk for:

Another overt HE episode

ONCE OVERT HE OCCURS:

within 12 months 4 in 10 patients will have a recurrence

4 in 10 patients
will have a recurrence



AFTER AN OVERT HE RECURRENCE:

within 6 months 4 in 10 patients will have another recurrence

4 in 10 patients
will have another
recurrence


Round button with nurse icon that reads Enroll in H.E.L.P. for support Round button with nurse icon that reads Enroll in H.E.L.P. for support

*Eligibility criteria, terms and conditions apply.

Risk of hospitalization

Hospitalization

Most people with overt HE will require hospitalization at some point.
Many will be hospitalized more than once.


In one study, nearly 4 in 10 people who had been hospitalized for overt
HE had to be hospitalized again within 30 days.

Worsening symptoms

Recent clinical trials suggest that problems with memory and learning could get worse after repeated episodes of overt HE.

THAT’S WHY IT’S SO IMPORTANT TO REDUCE THE RISK OF MORE EPISODES WITH HE MANAGEMENT 

The safety and efficacy of XIFAXAN in HE patients has not been studied for longer than 6 months in clinical trials.
If patients recover a significant amount of liver function, they may be able to discontinue HE therapy.

LEARN HOW OVERT HE CAN BE MANAGED

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment as this may cause increased effects of the medicine.
  • Tell your healthcare provider if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.
  • In clinical studies, the most common side effects of XIFAXAN were:
    • HE: peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).
    • IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please click here for full Prescribing Information.

See MoreImportant Safety Information
See LessImportant Safety Information

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment as this may cause increased effects of the medicine.
  • Tell your healthcare provider if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.
  • In clinical studies, the most common side effects of XIFAXAN were:
    • HE: peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).
    • IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please click here for full Prescribing Information.